Actively Recruiting
Phase 12 Study of EIS-12656 Alone or With PARP Inhibitor or Trastuzumab Deruxtecan in Patients With Advanced Solid Tumors Having Specific Genetic Mutations
Led by Eisbach Bio GmbH · Updated on 2024-09-19
144
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new drug called EIS-12656 in people with advanced or metastatic solid tumors that have specific homologous recombination deficient mutations. This Phase 12 trial aims to understand the safety, tolerability, and early effectiveness of EIS-12656 alone or combined with other cancer drugs such as a PARP inhibitor or Trastuzumab deruxtecan. The study focuses on patients who have progressed after at least one prior treatment or cannot tolerate other effective therapies. The study has two parts a Phase 1 dose escalation phase where participants receive increasing doses of EIS-12656 to find a safe and effective dose, followed by a Phase 2 dose expansion phase. In Phase 2, participants receive either EIS-12656 alone at the recommended dose or in combination with Olaparib a PARP inhibitor or Trastuzumab deruxtecan. EIS-12656 is given daily as tablets, and other drugs are given as per their standard usage guidelines. Participants will be monitored from the start of screening through treatment and follow-up periods lasting up to 7 months or more. Researchers will track side effects, dose-limiting toxicities, drug levels in the blood, tumor response, and progression-free survival. Safety is closely observed during and after treatment, including up to 45 days post last dose. The study includes regular assessments such as imaging and laboratory tests to evaluate treatment impact and participant health throughout the trial.
CONDITIONS
Brief Title
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Research Team
A
Adrian Schomburg
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here